L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients

• Status: Recruiting
• Trial end date: 2022-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. A potential signal driving sympathetic nerve activity (SNA) involves accumulation of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA). ADMA is elevated in CKD and is a strong, independent predictor of future cardiovascular events in these patients. .

The goal of this study is to determine whether overcoming the accumulation of endogenous ADMA with acute L-arginine infusion reduces SNA in CKD patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas at Arlington

Criteria

Inclusion Criteria:

• CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and 59 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine, age, gender, and race.

• Men and women 35 to 75 years of age

Exclusion Criteria:

• myocardial infarction

• heart failure

• anemia (hemoglobin <8 g/dl)

• cancer with current treatment

• previous organ transplantation

• immunosuppressant therapy

• human immunodeficiency virus infection

• pregnancy and/or lactating

• current tobacco use

• taking menopausal drugs (estradiol)

• treatment for diabetic neuropathy

• resting heart rate ≥ 100 bpm and

• systolic blood pressure ≤ 90 mmHg